Combination therapy for treating malignancies

US10653710B2 · kind B2 · utility

Assignees

• Agios Pharmaceuticals, Inc. · US
• CELGENE CORPORATION · US

Inventors

• Samuel V. Agresta · Lexington, US
• Krishnan Viswanadhan · East Hanover, US
• Jorge DiMartino · Belmont, US
• Vivek Saroj Kumar Chopra · South San Francisco, US
• Kyle MacBeth · Boston, US
• Robert Douglas Knight · Berkeley Heights, US
• Laurie A. Kenvin · New Hope, US
• Qiang Xu · Cupertino, US

Key dates

• Filing date: Oct 14, 2016
• Grant date: May 19, 2020
• Expiry date: Oct 18, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.